Searchable abstracts of presentations at key conferences in endocrinology

ea0026p244 | Pituitary | ECE2011

Hyperprolactinemia is a risk factor for radiological vertebral fractures in post-menopausal women

Mazziotti G , Mancini T , Mormando M , De Menis E , Bianchi A , Doga M , De Marinis L , Giustina A

Hyperprolactinemia may cause bone loss in pre-menopausal women and men. Data on fractures are scanty and it is still unclear which is the skeletal impact of hyperprolactinemia in post-menopausal women. The aim of this study was to evaluate the prevalence of vertebral fractures in post-menopausal women with hyperprolactinemia.Forty post-menopausal women (median age 57 years, range: 47–81) with prolactin (PRL)-secreting adenoma and 119 control post-me...

ea0029p992 | Growth hormone IGF axis - basic | ICEECE2012

C677T methylenetetrahydrofolate reductase gene polymorphism and colorectal neoplasms in acromegalic patients

Torre M. , Russo G. , Ragonese M. , Giandalia A. , Puglisi S. , De Menis E. , Arnaldi G. , Romanello G. , Cucinotta D. , Trimarchi F. , Cannavo S.

Introduction: Acromegalic patients have an increased risk of developing colorectal neoplasms (CN). A common polymorphism (C677T) in gene coding for methylenetetrahydrofolate reductase (MTHFR), a key enzyme in folate metabolism and in DNA synthesis, reparation and methylation, has been associated with CN risk in general population, but its role in acromegalic patients has never been explored yet.Aim: To investigate the contribution of MTHFR C677T polymorp...

ea0011p433 | Endocrine disruptors | ECE2006

A randomized, open-label, multicenter study to evaluate octreotide LAR with surgical therapy as primary therapy patients with acromegaly

Colao A , Bouterfa H , Cappabianca P , Caron P , De Menis E , Farrall A , Gadelha M , Reed A , Reincke M , Safari M , T’Sjoen G , Cuneo R

This is the first prospective study to compare the efficacy and safety of medical therapy and surgery as primary therapy in acromegaly.A total of 104 patients with untreated acromegaly were enrolled. Eighty-one patients randomized to receive either octreotide LAR 20 mg (n=40) or surgery (n=41) completed the 48 weeks treatment period, and constituted the population used for this analysis, regardless of response to treatment.<p class="abs...